RNA methyltransferases Inhibitors
1 drugsAbout RNA methyltransferases
RNA methyltransferases catalyze the addition of methyl groups to RNA, regulating splicing, stability, and translation. These enzymes are emerging as drug targets due to their role in critical cellular processes.
Currently, there is no genetic evidence linking RNA methyltransferases to specific diseases. However, the success of ONUREG in oncology suggests that modulating RNA methylation pathways can impact disease progression.
ONUREG (Bristol-Myers Squibb) is the only FDA-approved drug targeting RNA methyltransferases, approved in 2020 for oncology indications. It is a small molecule, highlighting the feasibility of modulating these enzymes for therapeutic benefit.
Strategic Insights
ℹ️ How we calculate- phase1 represents biological uncertainty with 42% completion.
Top RNA methyltransferases Drugs
Bristol-Myers Squibb is the only company with an approved drug targeting RNA methyltransferases.
The limited competitive landscape presents an opportunity for new entrants, but also indicates potential challenges in target validation.
RNA methyltransferases Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets RNA methyltransferases, using small molecule modality.
Explore alternative modalities like oligonucleotides or PROTACs to differentiate from existing approaches and expand therapeutic potential.
RNA methyltransferases Clinical Trials 523 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 244 | 78 | 72 | 86 | 52% |
| Phase 2 | 217 | 68 | 36 | 108 | 65% |
| Phase 3 | 56 | 15 | 13 | 27 | 54% |
| Phase 4 | 6 | 1 | 1 | 4 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved RNA methyltransferases drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting RNA methyltransferases. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
RNA methyltransferases Drug Approval Timeline (2020 - 2020)
The first and only drug, ONUREG, was approved in 2020.
The recent approval suggests growing interest, but further approvals are needed to confirm the target class's long-term viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 405 clinical trials targeting RNA methyltransferases.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities